PT1848413E - Terapia de combinação parentérica para afecções infecciosas com bactérias resistentes a fármacos - Google Patents

Terapia de combinação parentérica para afecções infecciosas com bactérias resistentes a fármacos Download PDF

Info

Publication number
PT1848413E
PT1848413E PT67113704T PT06711370T PT1848413E PT 1848413 E PT1848413 E PT 1848413E PT 67113704 T PT67113704 T PT 67113704T PT 06711370 T PT06711370 T PT 06711370T PT 1848413 E PT1848413 E PT 1848413E
Authority
PT
Portugal
Prior art keywords
combination therapy
drug resistant
resistant bacterium
infective conditions
parenteral combination
Prior art date
Application number
PT67113704T
Other languages
English (en)
Portuguese (pt)
Inventor
Manu Chaudhary
Original Assignee
Venus Remedies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venus Remedies Ltd filed Critical Venus Remedies Ltd
Publication of PT1848413E publication Critical patent/PT1848413E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT67113704T 2005-02-14 2006-02-08 Terapia de combinação parentérica para afecções infecciosas com bactérias resistentes a fármacos PT1848413E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN308DE2005 2005-02-14

Publications (1)

Publication Number Publication Date
PT1848413E true PT1848413E (pt) 2014-07-18

Family

ID=36337659

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67113704T PT1848413E (pt) 2005-02-14 2006-02-08 Terapia de combinação parentérica para afecções infecciosas com bactérias resistentes a fármacos

Country Status (15)

Country Link
US (2) US7960337B2 (enExample)
EP (1) EP1848413B1 (enExample)
JP (1) JP4918502B2 (enExample)
KR (2) KR20070085674A (enExample)
CN (1) CN101080221A (enExample)
AU (1) AU2006213441B2 (enExample)
BR (1) BRPI0607168A2 (enExample)
CA (1) CA2597812C (enExample)
ES (1) ES2482700T3 (enExample)
MX (1) MX2007009754A (enExample)
NZ (1) NZ555077A (enExample)
PT (1) PT1848413E (enExample)
UA (1) UA91208C2 (enExample)
WO (1) WO2006085337A1 (enExample)
ZA (1) ZA200704393B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080227732A1 (en) * 2005-05-13 2008-09-18 Venus Remedies Limited Treatment and Control of Severe Infections Including Cystic Fibrosis
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
GB2459126A (en) * 2008-04-10 2009-10-14 Peter Wilson Antimicrobial agent
CA2768582C (en) * 2009-07-24 2017-02-14 University Of Tennessee Research Foundation Spectinamides as anti-tuberculosis agents
CA2781666C (en) * 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
JP5913367B2 (ja) 2011-01-05 2016-04-27 ホスピーラ インコーポレイテッド バンコマイシンの噴霧乾燥
ITLO20110001A1 (it) * 2011-05-03 2012-11-04 Fisiopharma Srl Flaconi di vancomicina cloroidrata con stabilità migliorata
RU2491921C1 (ru) * 2012-07-11 2013-09-10 Общество с ограниченной ответственностью "Опытно-технологическая фирма "Этрис" Способ лечения мастита у коров в сухостойный период
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
WO2014151845A1 (en) 2013-03-15 2014-09-25 Scuderi Group, Inc. Split-cycle engines with direct injection
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
KR102329764B1 (ko) 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
BE1021242B1 (nl) * 2014-06-11 2015-09-08 Neogen N.V. Teicoplanine lyofilisaten
WO2016071495A1 (en) 2014-11-06 2016-05-12 Xellia Pharmaceuticals Aps Glycopeptide compositions
DK3416669T3 (da) * 2016-02-19 2025-08-18 Klaus Brandenburg Midler og metoder til behandling af bakterielle infektioner
MX388732B (es) 2016-05-09 2025-03-20 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados
CN107661470A (zh) * 2016-08-29 2018-02-06 成都特兰辰亚生物科技有限公司 添加有萘夫西林钠治疗痢疾的组合物
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US11433115B2 (en) 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775533A (en) 1987-02-24 1988-10-04 Erbamont, Inc. Reconstitution of dry fill cyclophosphamide
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
GB9500978D0 (en) 1995-01-19 1995-03-08 Smithkline Beecham Plc Pharmaceutical formulations
AU6698496A (en) 1995-07-17 1997-02-18 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Metal-containing ribonucleotide polypeptides
JP4142149B2 (ja) * 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US7378408B2 (en) 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection

Also Published As

Publication number Publication date
EP1848413B1 (en) 2014-04-09
NZ555077A (en) 2010-03-26
ZA200704393B (en) 2008-09-25
UA91208C2 (ru) 2010-07-12
US8778873B2 (en) 2014-07-15
EP1848413A1 (en) 2007-10-31
JP4918502B2 (ja) 2012-04-18
ES2482700T3 (es) 2014-08-04
AU2006213441A1 (en) 2006-08-17
WO2006085337B1 (en) 2006-11-02
AU2006213441B2 (en) 2011-12-01
BRPI0607168A2 (pt) 2009-08-11
KR20090052893A (ko) 2009-05-26
CA2597812C (en) 2012-01-24
MX2007009754A (es) 2007-11-07
JP2008530082A (ja) 2008-08-07
US20110257079A1 (en) 2011-10-20
US7960337B2 (en) 2011-06-14
CN101080221A (zh) 2007-11-28
US20080188403A1 (en) 2008-08-07
CA2597812A1 (en) 2006-08-17
WO2006085337A1 (en) 2006-08-17
KR20070085674A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
ZA200704393B (en) Parenteral combination therpy for infective conditions with drug resistant bacterium
PL1912671T3 (pl) Koniugaty beta-glukuronid-linker-lek
IL246548A0 (en) Pharmaceutical forms with improved pharmacokinetic properties
IL178557A0 (en) Safety infusion set
PH12012501503A1 (en) Immobilized 1,2-benzisothiazolin-3-one
AP2008004533A0 (en) Pharmaceutical combination
ZA200603961B (en) Hanger arrangement
IL190323A0 (en) Kit for the parenteral administration of drugs
IL197883A0 (en) Combination drug
GB2422151B (en) Opacifying Polymers
EP1846698A4 (en) SCREENS FOR IGNERS
PL1934252T3 (pl) Sposób wytwarzania koniugatów insuliny
ZA200701287B (en) Hanger arrangement
GB0514193D0 (en) Heat resistant means
ZA200804666B (en) Pharmaceutical combination
GB0517363D0 (en) Child resistant roll-and-press lighter
TWI372053B (en) Combination drug
EP1869271A4 (en) SUPPORT
GB0518439D0 (en) Soother
GB0602094D0 (en) The arc
GB0602684D0 (en) Bracket
GB0622648D0 (en) The body bouncer
GB0502541D0 (en) Medicament
GB0520196D0 (en) Furnace
GB0616829D0 (en) Pre text mate